Management of Benign Prostatic Hyperplasia with Overactive Bladder: Insights from Indian Clinical Practice

Goto Gangkak; Mukut Debnath; Ashok Kumar Gupta; Shyam Agrawal

doi:10.36948/ijfmr.2025.v07i05.58355

Management of Benign Prostatic Hyperplasia with Overactive Bladder: Insights from Indian Clinical Practice

Author(s)	Dr. Goto Gangkak, Dr. Mukut Debnath, Dr. Ashok Kumar Gupta, Dr. Shyam Agrawal
Country	India
Abstract	Abstract Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) frequently present with overlapping lower urinary tract symptoms (LUTS). The association between BPH and OAB-related storage symptoms remains a significant clinical concern. Despite symptom overlap, OAB is often underdiagnosed and undertreated in men with BPH, emphasising the need for a more symptom-focused approach. A survey was conducted among physicians to assess their clinical perspectives on the diagnosis, prevalence, symptoms and management of BPH with concomitant OAB. Physicians provided their insights, and data were analysed to identify trends in treatment strategies and physician preferences for combination therapy of Silodosin and Mirabegron. The prevalence of OAB symptoms in BPH patients varied, with most physicians (49.6%) reporting a 40%–60% overlap. Frequent symptoms included urinary frequency (77.8%) and urgency (77.0%), followed by nocturia and urge incontinence. The diagnosis was primarily based on clinical history, urodynamic assessments and imaging. The combination therapy of Silodosin and Mirabegron emerged as the preferred treatment, with 82.5% of physicians endorsing its use. Combination therapy has been reported to improve symptom relief, enhance compliance and provide synergistic benefits. Patient adherence to treatment remained moderate, with 58.1% of physicians reporting adherence rates between 50% and 75%. The findings highlight the complexity of managing LUTS in men with BPH and OAB. Although BPH is more frequently diagnosed and treated, the underdiagnosis of OAB necessitates improved awareness and targeted management. Combination therapy with Silodosin and Mirabegron offers significant symptomatic relief and is widely preferred by clinicians, highlighting its role in optimising treatment outcomes.
Keywords	Benign prostatic hyperplasia; Bladder outlet obstruction; Lower urinary tract symptoms; Overactive bladder; Silodosin and Mirabegron; Voiding symptoms
Field	Medical / Pharmacy
Published In	Volume 7, Issue 5, September-October 2025
Published On	2025-10-31
DOI	https://doi.org/10.36948/ijfmr.2025.v07i05.58355

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 2 Cover Page Vol 8 Isu 1 Cover Page Vol 7 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Management of Benign Prostatic Hyperplasia with Overactive Bladder: Insights from Indian Clinical Practice

Share this